Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8709099rdf:typepubmed:Citationlld:pubmed
pubmed-article:8709099lifeskim:mentionsumls-concept:C0031640lld:lifeskim
pubmed-article:8709099lifeskim:mentionsumls-concept:C0064971lld:lifeskim
pubmed-article:8709099lifeskim:mentionsumls-concept:C0282556lld:lifeskim
pubmed-article:8709099lifeskim:mentionsumls-concept:C1849508lld:lifeskim
pubmed-article:8709099lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:8709099lifeskim:mentionsumls-concept:C0027375lld:lifeskim
pubmed-article:8709099lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:8709099lifeskim:mentionsumls-concept:C1412691lld:lifeskim
pubmed-article:8709099lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:8709099lifeskim:mentionsumls-concept:C1149866lld:lifeskim
pubmed-article:8709099lifeskim:mentionsumls-concept:C0243077lld:lifeskim
pubmed-article:8709099lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:8709099lifeskim:mentionsumls-concept:C0205549lld:lifeskim
pubmed-article:8709099lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:8709099lifeskim:mentionsumls-concept:C0205460lld:lifeskim
pubmed-article:8709099pubmed:issue14lld:pubmed
pubmed-article:8709099pubmed:dateCreated1996-9-10lld:pubmed
pubmed-article:8709099pubmed:abstractTextA series of 1-aryl-2,3-bis(hydroxymethyl)naphthalene lignans have been synthesized and evaluated for their ability to selectively inhibit PDE IV isolated from guinea pig. Replacement of the 1-phenyl ring by a pyridone ring led to marked improvement of their selectivity for PDE IV over PDE III. The compounds that were most potent and selective involved those bearing an N-alkylpyridone ring at C-1. These compounds also showed potent antispasmogenic activity without causing significant changes in heart rate in the guinea pig. The most potent compound was 6,7-diethoxy-2, 3-bis(hydroxymethyl)-1-[1-(2-methoxyethyl)-2-oxo-pyrid-4-yl]nap hth alene (17f), ED50 values of histamine-induced and antigen-induced bronchoconstriction in the guinea pig being 0.08 and 2.3 mg/kg iv, respectively. This compound was chosen as a candidate for further pharmacological evaluation.lld:pubmed
pubmed-article:8709099pubmed:languageenglld:pubmed
pubmed-article:8709099pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8709099pubmed:citationSubsetIMlld:pubmed
pubmed-article:8709099pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8709099pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8709099pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8709099pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8709099pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8709099pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8709099pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8709099pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8709099pubmed:statusMEDLINElld:pubmed
pubmed-article:8709099pubmed:monthJullld:pubmed
pubmed-article:8709099pubmed:issn0022-2623lld:pubmed
pubmed-article:8709099pubmed:authorpubmed-author:YamagataSSlld:pubmed
pubmed-article:8709099pubmed:authorpubmed-author:SugiuraMMlld:pubmed
pubmed-article:8709099pubmed:authorpubmed-author:IwasakiTTlld:pubmed
pubmed-article:8709099pubmed:authorpubmed-author:KondoKKlld:pubmed
pubmed-article:8709099pubmed:authorpubmed-author:IkezawaKKlld:pubmed
pubmed-article:8709099pubmed:authorpubmed-author:KurodaTTlld:pubmed
pubmed-article:8709099pubmed:authorpubmed-author:MoritaniYYlld:pubmed
pubmed-article:8709099pubmed:authorpubmed-author:KikkawaHHlld:pubmed
pubmed-article:8709099pubmed:authorpubmed-author:KaminumaOOlld:pubmed
pubmed-article:8709099pubmed:issnTypePrintlld:pubmed
pubmed-article:8709099pubmed:day5lld:pubmed
pubmed-article:8709099pubmed:volume39lld:pubmed
pubmed-article:8709099pubmed:ownerNLMlld:pubmed
pubmed-article:8709099pubmed:authorsCompleteYlld:pubmed
pubmed-article:8709099pubmed:pagination2696-704lld:pubmed
pubmed-article:8709099pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:8709099pubmed:meshHeadingpubmed-meshheading:8709099-...lld:pubmed
pubmed-article:8709099pubmed:meshHeadingpubmed-meshheading:8709099-...lld:pubmed
pubmed-article:8709099pubmed:meshHeadingpubmed-meshheading:8709099-...lld:pubmed
pubmed-article:8709099pubmed:meshHeadingpubmed-meshheading:8709099-...lld:pubmed
pubmed-article:8709099pubmed:meshHeadingpubmed-meshheading:8709099-...lld:pubmed
pubmed-article:8709099pubmed:meshHeadingpubmed-meshheading:8709099-...lld:pubmed
pubmed-article:8709099pubmed:meshHeadingpubmed-meshheading:8709099-...lld:pubmed
pubmed-article:8709099pubmed:meshHeadingpubmed-meshheading:8709099-...lld:pubmed
pubmed-article:8709099pubmed:meshHeadingpubmed-meshheading:8709099-...lld:pubmed
pubmed-article:8709099pubmed:meshHeadingpubmed-meshheading:8709099-...lld:pubmed
pubmed-article:8709099pubmed:meshHeadingpubmed-meshheading:8709099-...lld:pubmed
pubmed-article:8709099pubmed:meshHeadingpubmed-meshheading:8709099-...lld:pubmed
pubmed-article:8709099pubmed:meshHeadingpubmed-meshheading:8709099-...lld:pubmed
pubmed-article:8709099pubmed:year1996lld:pubmed
pubmed-article:8709099pubmed:articleTitleNovel selective PDE IV inhibitors as antiasthmatic agents. Synthesis and biological activities of a series of 1-aryl-2,3-bis(hydroxymethyl)naphthalene lignans.lld:pubmed
pubmed-article:8709099pubmed:affiliationLead Optimization Research Laboratory, Tanàbe Seiyaku Company, Ltd., Osaka, Japan.lld:pubmed
pubmed-article:8709099pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8709099pubmed:publicationTypeIn Vitrolld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:8709099lld:chembl